List of Studies ( Metabolite:Myristoyl-CoA)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Blood | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Brain | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Heart | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Liver | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Blood | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Brain | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Heart | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Liver | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003435 | AN005643 | Metabolomics analysis of zebrafish embryos treated with rotenone, Fasnall, TVB-2640, and GSK2194069 | Media | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST003435 | AN005644 | Metabolomics analysis of zebrafish embryos treated with rotenone, Fasnall, TVB-2640, and GSK2194069 | Media | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST003434 | AN005641 | Plasma concentrations of Fasnall in mice after a bolus of 10 mg/kg administered intraperitoneally. | Blood | Human | Cancer | Wistar Institute | LC-MS |
| ST003434 | AN005642 | Plasma concentrations of Fasnall in mice after a bolus of 10 mg/kg administered intraperitoneally. | Blood | Human | Cancer | Wistar Institute | LC-MS |
| ST003433 | AN005639 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate, Fasnall, and GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003433 | AN005640 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate, Fasnall, and GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003432 | AN005637 | Intracellular and medium metabolomics of BT-474 cells treated with LW6 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003432 | AN005638 | Intracellular and medium metabolomics of BT-474 cells treated with LW6 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003431 | AN005635 | Metabolomics analysis of breast cancer cell lines treated with dimethylmalonate (DMM), GSK2194069, and their combination. | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003431 | AN005636 | Metabolomics analysis of breast cancer cell lines treated with dimethylmalonate (DMM), GSK2194069, and their combination. | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003430 | AN005633 | Intracellular and medium metabolomics of BT-474 cells treated with GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003430 | AN005634 | Intracellular and medium metabolomics of BT-474 cells treated with GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003429 | AN005631 | Intracellular and medium metabolomics of BT-474 cells treated with Fasnall that was manufactured by Enamine | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003429 | AN005632 | Intracellular and medium metabolomics of BT-474 cells treated with Fasnall that was manufactured by Enamine | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003428 | AN005629 | Intracellular and medium metabolomics of BT-474 cells treated with rotenone | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003428 | AN005630 | Intracellular and medium metabolomics of BT-474 cells treated with rotenone | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003427 | AN005627 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate | Breast cancer cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003427 | AN005628 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate | Breast cancer cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003412 | AN005604 | Intracellular and medium metabolomics for BT-474 cells treated with cerulenin, TVB-2640, and TVB-3166 for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003412 | AN005605 | Intracellular and medium metabolomics for BT-474 cells treated with cerulenin, TVB-2640, and TVB-3166 for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003411 | AN005602 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h (C75 MRM included) | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003411 | AN005603 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h (C75 MRM included) | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003367 | AN005518 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003367 | AN005519 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003366 | AN005516 | Malate dehydrogenase (MDH) inhibition assay: Fasnall does not affect MDH activity in vitro | Synthetic | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST003366 | AN005517 | Malate dehydrogenase (MDH) inhibition assay: Fasnall does not affect MDH activity in vitro | Synthetic | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST002663 | AN004335 | MoTrPAC: Endurance exercise training study in young adult rats, Rat White Adipose Powder - Targeted Acyl-CoA | White adipose | Rat | Duke University | LC-MS | |
| ST002662 | AN004334 | MoTrPAC: Endurance exercise training study in young adult rats, Rat Liver Powder - Targeted Acyl-CoA | Liver | Rat | Duke University | LC-MS | |
| ST002661 | AN004333 | MoTrPAC: Endurance exercise training study in young adult rats, Rat Heart Powder - Targeted Acyl-CoA | Heart | Rat | Duke University | LC-MS | |
| ST002660 | AN004332 | MoTrPAC: Endurance exercise training study in young adult rats, Rat Gastrocnemius Powder - Targeted Acyl-CoA | Gastrocnemius | Rat | Duke University | LC-MS | |
| ST002078 | AN003387 | Multiple modes of interfering with the activity of Plasmodium falciparum cytoplasmic isoleucyl-tRNA synthetase illustrate the enzyme is a promising antimalarial target. | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST002078 | AN003388 | Multiple modes of interfering with the activity of Plasmodium falciparum cytoplasmic isoleucyl-tRNA synthetase illustrate the enzyme is a promising antimalarial target. | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST002011 | AN003278 | The anticancer human mTOR inhibitor MLN0128/Sapanisertib with potent multistage in vitro antiplasmodium activity and in vivo antimalarial efficacy in a humanised mouse model is an inhibitor of multiple Plasmodium falciparum kinases. | Blood | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST001232 | AN002050 | Combining stage - specificity and metabolomic profiling to advance drug discovery for malaria | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST001149 | AN001896 | Plasmodium Niemann-Pick Type C1-Related Protein is a Druggable Target Required for Parasite Membrane Homeostasis | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST001066 | AN001744 | Lipidomics analysis for aged mice liver (part-III) | Adipose tissue | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001066 | AN001744 | Lipidomics analysis for aged mice liver (part-III) | Brain | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001066 | AN001744 | Lipidomics analysis for aged mice liver (part-III) | Liver | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001066 | AN001744 | Lipidomics analysis for aged mice liver (part-III) | Muscle | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST000115 | AN000196 | Impact of insulin deprivation and treatment on sphingolipid distribution in different muscle subcellular compartments of streptozotocin-diabetic C57Bl/6 mice | Muscle | Mouse | Diabetes | Mayo Clinic | LC-MS |
